Novan Inc (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
47
About the Report
About the Report
Summary
Novan Inc (Novan) is a clinical-stage pharmaceutical company that develops nitric oxide therapies for the treatment of dermatological and oncovirus-mediated diseases. The company's pipeline products are being developed for the treatment of acne vulgaris; genital warts; for onychomycosis and for treatment of psoriasis and atopic dermatitis. Novan uses its proprietary technology Nitricil, to customize macromolecular delivery of nitric oxide and store gaseous species which result in nitric oxide-releasing new chemical entities for healthcare applications. The company's products find application in the treatment of dermatology disorders. It works in collaboration with academic institutions, public and private companies and other universities. Novan is headquartered in Morrisville, North Carolina, the US.
Novan Inc (NOVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Novan Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novan Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Novan Acquires Intellectual Property Rights From KNOW Bio 11
Venture Financing 12
Novan Raises Additional USD2.4 Million in Venture Financing 12
Novan Raises USD30.4 Million in Financing Round 13
Novan Raises Additional USD39.7 Million in Venture Financing 14
Novan Raises USD10.3 Million in Venture Financing 15
Novan Raises USD3.5 Million in Venture Financing 16
Novan Raises USD 11 Million In Series D Financing 17
Licensing Agreements 18
Sato Pharma Amends Licensing Agreement with Novan 18
Know Bio Enters into Sub-Licensing Agreement with Novan 20
Know Bio Enters into Licensing Agreement with Novan 21
Novan Enters into Licensing Agreement with University of Akron Research Foundation 22
Equity Offering 23
Novan Raises USD38 Million in Public Offering of Shares 23
Novan Plans to Raise Funds through Public Offering of Shares 24
Novan Raises USD51.9 Million in IPO 25
Novan Inc-Key Competitors 26
Novan Inc-Key Employees 27
Novan Inc-Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
May 12, 2017: Novan Reports First Quarter 2017 Financial Results 29
Mar 20, 2017: Novan Reports Fourth Quarter and Full Year 2016 Financial Results 30
Corporate Communications 32
Apr 12, 2018: Novan Advances Organization and Strengthens Leadership Team 32
Feb 21, 2018: Dr. Eugene Sun Appointed to Novan Board of Directors 33
Jan 19, 2018: Novan Announces Resignation Of William L. Hodges As Interim Chief Financial Office 34
Sep 26, 2017: Machelle Sanders Appointed to Novan Board of Directors 35
Aug 16, 2017: Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors 36
Jun 05, 2017: Novan Announces Leadership Adjustments and Business Update 37
Mar 22, 2017: Novan Reshapes Executive Management Team 39
Clinical Trials 41
May 17, 2018: SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment 41
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference 42
Dec 05, 2017: Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414 44
Apr 27, 2017: Novan Presents Preclinical Data from Inflammatory Skin Diseases Program 45
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Figure
List of Figures
Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Novan Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novan Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Novan Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Novan Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Novan Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Novan Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novan Acquires Intellectual Property Rights From KNOW Bio 11
Novan Raises Additional USD2.4 Million in Venture Financing 12
Novan Raises USD30.4 Million in Financing Round 13
Novan Raises Additional USD39.7 Million in Venture Financing 14
Novan Raises USD10.3 Million in Venture Financing 15
Novan Raises USD3.5 Million in Venture Financing 16
Novan Raises USD 11 Million In Series D Financing 17
Sato Pharma Amends Licensing Agreement with Novan 18
Know Bio Enters into Sub-Licensing Agreement with Novan 20
Know Bio Enters into Licensing Agreement with Novan 21
Novan Enters into Licensing Agreement with University of Akron Research Foundation 22
Novan Raises USD38 Million in Public Offering of Shares 23
Novan Plans to Raise Funds through Public Offering of Shares 24
Novan Raises USD51.9 Million in IPO 25
Novan Inc, Key Competitors 26
Novan Inc, Key Employees 27
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.